Short Sellers Stung by Regeneron
Regeneron Pharmaceuticals (REGN) has emerged as one of the most costly stocks for short sellers in recent months. As the company's share price has demonstrated resilience, those who bet against the stock have been forced to cover, further fueling the upward momentum.
The Cost of Being Wrong
Shorting biotech stocks like Regeneron carries inherent risks, particularly when clinical data or market performance exceeds expectations. Ortex data highlights that the aggregate short interest in the sector has been volatile, but Regeneron specifically has stood out as a name where short sellers have faced significant mark-to-market losses.
Key Takeaways
- Regeneron was a top source of short-seller losses in recent reporting periods.
- Biotech sector short interest remains highly sensitive to news flow.
- Short covering has likely contributed to the stock's recent price strength.
The Bottom Line
Regeneron serves as a reminder of the dangers of shorting high-conviction biotech names. The losses incurred by bears here underscore the importance of monitoring real-time short interest rather than relying on stale data.
Signal data sourced from Ortex. This post is an original analysis prepared by The Forensic Ledger from publicly available data. Not investment advice.
Not investment advice. This is original reporting and analysis prepared by The Forensic Ledger from publicly available data. Nothing here is a recommendation to buy, sell, or hold any security. Always consult the original source and a licensed professional. See our full disclaimer and source-citation policy.